TrisoNIM, first prenatal test non invasive sensing Down, Edwards and Patau syndrome.

-a simple blood test, without risk for the fetus or the mother. Innovation and technology Spanish.

-in Spain occur approximately 470,000 annual births. The age of pregnant women has been increasing and the risks have grown in parallel. Access to the test could prevent 98% of the more than 35,000 amniocentesis performed in Spain each year and that entail risks such as miscarriage of the fetus or the intrauterine infection

-a – 5 milliliters of the mother’s blood analysis – just the anguish of the pregnant and can avoid the risks of amniocentesis. The test detects Down, Edwards and Patau syndromes, is done from the first trimester of pregnancy, with results in 3 weeks, with an accuracy of 99.9% to rule out Down syndrome

– is the only test currently in marketing in the domestic market, which used massive full genome sequencing. This test has been co-developed by NIMGenetics, the Spanish leader in genetic diagnosis. It’s a technology clinically validated and endorsed by prestigious scientific publications. Allows an early detection of trisomies and facilitates clinical decision

Spain, January 2013.- NIMGenetics, Spanish leader in genetic diagnosis with clinical applicability, presents TrisoNIM, prenatal testing test noninvasive, recent launch in Spainwhich allows the early detection of chromosomal abnormalities, such as the Down syndrome, Edwards syndrome and Patau syndrome470,000 Births that occur in our country each year, in many cases the age of pregnant women has been increasing and thereby risks have grown in parallel. Here that at present some 35,000 amniocentesis carried a year in Spain, a test-invasive which carries risks rigged as the miscarriage of the fetus or intrauterine infection, in addition to the logical inconvenience and rest periods. Access to prenatal diagnosis TrisoNIM test could prevent up to 98% of those more than 35,000 amniocentesis pregnant Spanish carried each year, thus preventing the associated risks.

TrisoNIM is based on the analysis of the DNA of the fetus, being present in the mother’s blood during pregnancy. The test catches it and sequence, detecting trisomies. A test that ends with the anguish of the pregnant woman and which avoids any risk of an amniocentesis is performed with only an analysis of 5 milliliters of blood from the mother. The test detects Down, Edwards and Patau syndromes.

A simple blood test allows this test of prenatal genetic testing to finish with the maternal anguish of quickly, effectively, easily and securely. The price of the test around 800 euros, you can perform from the twelfth week of gestation and results are ready in about 3 weeks, with total accuracy to rule out Down syndrome.

The gynecologist can inform pregnant women about this test and prescribe it. You can also contact NIMGenetics to receive information about TrisoNIM in query 687467413 phone and email trisonim@nimgenetics.com or via your www.nimgenetics.com page, although they must always have your health care professional.

NIMGenetics began the research which resulted in a prenatal genetic test in 2009, always with their own scientific resources, and has developed hand in hand with international partners. The test is being marketed in Spain since the month of August.

About NIMGenetics

NIMGenetics, Spanish leader in its segment of activity, is a pioneer in the development and commercialization of genetic diagnostic tests. With five years of permanence in the sector, it foresees a growth of 200% for the biennium 2013-2014. Invests in own developments in know-how and add permanently innovative talent to its team. It has a permanent staff of 15 scientific experts and invoice about one million euros. In two years they expect duplicate template and multiply by four the billing. The capital of the company belongs mostly to its founding, researchers partners who develop their work within the company, and a venture capital company. Among its plans in the medium term is the international marketing of its services of genetic diagnosis, which will start with the introduction in 2013 in Mexico. It is a company of reference in clinical genetics and molecular biology, specializing in the genetic diagnosis with clinical applicability. It is a Spanish entrepreneurial company that has positioned itself as the number one in biotechnological innovation in five years.